Search

Additional file 1: Figure S1. The structure of Compound 12. Chemical name: 7-[5-Chloro-2-(2,4-dimethoxy-phenylamino)-pyrimidin-4-ylamino]-2-methyl-4-[4-(4-methyl-piperazin-1-yl)-piperidin-1-yl]-2,3-dihydro-isoindol-1-one.

Additional file 4: Figure S3. Atherosclerotic lesion area analysis. Atherosclerotic lesion area was evaluated in the aorta by en face analysis (A) and in aortic root by cross-sectional analysis (B).

Additional file 2: Table S2. Effects of TAE226 on MIA PaCa-2 subcutaneous tumor growth and body weight change.

Additional file 2: Table S1. IC50 values; Kinase inhibition selectivity of compound 12.

Additional file 3: Figure S2. Overview of efficacy trials. (A) Prevention in apoE KO mice, (B) therapeutic intervention in apoE KO mice (6 + 6 weeks) and LDLr KO mice (8 + 8 weeks).

Additional file 5: Table S2. Clinical biochemistry markers; Data expressed as meanâ Âąâ SEM.

Additional file 3: Table S3. Eďťżffects of TAE226 on 4T1 primary tumor growth, body weight change and lung metastasis.

Additional file 1: Table S1. Plating density of cell lines used in panel screening.

Decreased calf muscle volume in CT-26 colon cancer-bearing mice. Calf muscle volume assessed non-invasively by MRI at the time-point of treatment initiation. Values are expressed as percentage change from basal ± SEM; ** P